| Associate Editors |
|
iii | |
| Contributors |
|
v | |
| Preface: Sorting Through the Confusion |
|
xxiii | |
|
|
| Section I Cornea and External Diseases |
|
|
Novel Diagnostics and Therapeutics in Dry Eye Disease |
|
|
|
|
|
|
|
|
|
|
|
2 | (1) |
|
|
|
2 | (8) |
|
|
|
2 | (1) |
|
|
|
3 | (2) |
|
|
|
5 | (1) |
|
Matrix Metalloproteinase-9 Detection |
|
|
6 | (1) |
|
|
|
7 | (2) |
|
|
|
9 | (1) |
|
|
|
10 | (5) |
|
|
|
10 | (1) |
|
|
|
11 | (1) |
|
|
|
12 | (1) |
|
|
|
12 | (1) |
|
|
|
12 | (1) |
|
|
|
13 | (2) |
|
|
|
15 | (1) |
|
|
|
15 | (6) |
|
Review of Descemet Stripping Automated Endothelial Keratoplasty Versus Descemet Membrane Endothelial Keratoplasty |
|
|
|
|
|
|
|
21 | (1) |
|
|
|
22 | (5) |
|
|
|
22 | (1) |
|
|
|
23 | (2) |
|
|
|
25 | (1) |
|
|
|
26 | (1) |
|
|
|
26 | (1) |
|
Transitioning from Descemet stripping automated endothelial keratoplasty to Descemet membrane endothelial keratoplasty |
|
|
26 | (1) |
|
Patient selection and counseling |
|
|
27 | (1) |
|
|
|
27 | (1) |
|
|
|
28 | (3) |
| Section II Cataract and Refractive Surgery |
|
|
Pseudoexfoliation Syndrome and Cataract Surgery |
|
|
|
|
|
Video content accompanies this article at: www.advancesinophthalmology.com. |
|
|
|
|
|
31 | (1) |
|
|
|
32 | (10) |
|
|
|
33 | (8) |
|
The IOL selection in pseudoexfoliation syndrome |
|
|
41 | (1) |
|
|
|
42 | (3) |
|
The Use of Temporary and Permanent Capsular Devices in Eyes with Compromised Zonules |
|
|
|
|
|
Video content accompanies this article at: www.advancesinophthalmology.com. |
|
|
|
|
|
45 | (1) |
|
|
|
46 | (2) |
|
Capsular tension segments |
|
|
48 | (2) |
|
|
|
50 | (1) |
|
Modified capsular tension rings |
|
|
50 | (1) |
|
|
|
51 | (2) |
| Section III Uveitis |
|
|
Therapeutic Options and Strategies for the Uveitis Patient |
|
|
|
|
|
|
|
53 | (1) |
|
|
|
54 | (2) |
|
Present relevance and future avenues to consider or to investigate; how this article may change the approach to the subject |
|
|
56 | (1) |
|
|
|
57 | (2) |
|
Follow-up on the Longitudinal Study of the Ocular Complications of Human Immunodeficiency Virus/AIDS |
|
|
|
|
|
|
|
|
|
59 | (1) |
|
|
|
60 | (1) |
|
|
|
60 | (2) |
|
Non-cytomegalovirus retinitis infections |
|
|
62 | (1) |
|
Noninfectious ocular complications |
|
|
63 | (1) |
|
|
|
63 | (1) |
|
Epidemiology and discussion |
|
|
63 | (1) |
|
Age-related macular degeneration |
|
|
64 | (1) |
|
|
|
64 | (1) |
|
Human immunodeficiency virus neuroretinal disorder |
|
|
64 | (1) |
|
|
|
65 | (4) |
|
|
|
|
|
|
|
|
|
|
69 | (1) |
|
|
|
70 | (1) |
|
Associated systemic and local diseases |
|
|
71 | (1) |
|
|
|
71 | (2) |
|
|
|
73 | (6) |
|
|
|
73 | (1) |
|
|
|
73 | (1) |
|
Signs/associated clinical findings |
|
|
74 | (2) |
|
|
|
76 | (1) |
|
|
|
77 | (2) |
|
|
|
79 | (2) |
|
|
|
80 | (1) |
|
|
|
80 | (1) |
|
Laser photocoagulation and anti-vascular endothelial growth factor |
|
|
81 | (1) |
|
|
|
81 | (1) |
|
|
|
82 | (3) |
| Section IV Vitreoretinal Disease |
|
|
Recent Innovations in Stem Cell Therapy for Retinal Disease |
|
|
|
|
|
|
|
|
|
85 | (1) |
|
|
|
86 | (3) |
|
|
|
87 | (1) |
|
|
|
88 | (1) |
|
Induced pluripotent stem cells |
|
|
89 | (1) |
|
|
|
89 | (1) |
|
Neural stem cells or human central nervous system stem cells |
|
|
89 | (1) |
|
|
|
89 | (1) |
|
Very small embryonic-like stem cells |
|
|
89 | (1) |
|
|
|
90 | (1) |
|
|
|
90 | (1) |
|
Mechanisms of stem cell transplantation |
|
|
90 | (2) |
|
Diseases treated with stem cell therapy |
|
|
92 | (8) |
|
Age-related macular degeneration |
|
|
92 | (8) |
|
|
|
100 | (2) |
|
|
|
100 | (1) |
|
Ongoing research and clinical trials |
|
|
100 | (2) |
|
|
|
102 | (3) |
|
|
|
102 | (1) |
|
Ongoing research and clinical trials |
|
|
102 | (3) |
|
|
|
105 | (2) |
|
|
|
107 | (4) |
|
Updates on the Management of Diabetic Macular Edema with New-Generation Intravitreal Injectable Drugs |
|
|
|
|
|
|
|
|
|
111 | (3) |
|
|
|
111 | (1) |
|
|
|
112 | (1) |
|
|
|
112 | (2) |
|
Diabetic macular edema management |
|
|
114 | (9) |
|
Systemic risk factor control |
|
|
114 | (1) |
|
|
|
114 | (1) |
|
|
|
115 | (1) |
|
Intravitreal injection of vitreolysis agents |
|
|
115 | (1) |
|
Intravitreal injection of corticosteroids |
|
|
115 | (1) |
|
Nonsteroidal anti-inflammatory drugs |
|
|
116 | (1) |
|
Intravitreal injection of anti-vascular endothelial growth factor agents |
|
|
117 | (3) |
|
New-generation intravitreal injectable drugs in development |
|
|
120 | (3) |
|
|
|
123 | (6) |
|
|
|
126 | (3) |
|
27-Gauge Vitrectomy: The Future of Posterior Segment Surgery? |
|
|
|
|
|
|
|
|
|
|
|
129 | (2) |
|
The road to minimally invasive vitreous surgery |
|
|
129 | (1) |
|
Twenty-seven gauge vitrectomy |
|
|
130 | (1) |
|
|
|
131 | (1) |
|
|
|
131 | (1) |
|
Improved vitrector speed and precision |
|
|
131 | (1) |
|
Intraoperative optical coherence tomography |
|
|
132 | (1) |
|
|
|
132 | (1) |
|
|
|
133 | (2) |
| Section V Oculoplastics |
|
|
The Ultrasonic Bone Aspirator in Endoscopic Dacryocystorhinostomy |
|
|
|
|
|
|
|
|
|
135 | (1) |
|
External dacryocystorhinostomy and endoscopic dacryocystorhinostomy: a brief history |
|
|
136 | (1) |
|
The ultrasonic bone aspirator: an overview |
|
|
136 | (5) |
|
Endoscopic dacryocystorhinostomy: a brief description of the procedure |
|
|
139 | (2) |
|
|
|
141 | (3) |
|
Success rates of endoscopic dacryocystorhinostomy and its counterparts in the literature |
|
|
142 | (1) |
|
Surgical success of the ultrasonic bone aspirator in endoscopic dacryocystorhinostomy |
|
|
142 | (1) |
|
Factors affecting success rates |
|
|
143 | (1) |
|
Time taken to perform the osteotomy |
|
|
143 | (1) |
|
|
|
143 | (1) |
|
Advantages of the ultrasonic bone aspirator |
|
|
144 | (1) |
|
|
|
144 | (4) |
|
Orbital Manifestations of Immunoglobulin G4-Related Disease: Current State of Knowledge |
|
|
|
|
|
|
|
|
|
|
|
|
|
148 | (2) |
|
Systemic immunoglobulin G4-related disease |
|
|
150 | (12) |
|
Definition and diagnosis of immunoglobulin G4-related disease |
|
|
150 | (1) |
|
Histologic diagnosis of immunoglobulin G4-related disease |
|
|
150 | (2) |
|
Epidemiology, etiology, and clinical relevance of immunoglobulin G4-related disease |
|
|
152 | (1) |
|
Orbital immunoglobulin G4-related disease |
|
|
153 | (1) |
|
Presentation and differential diagnosis of immunoglobulin G4-related orbital disease |
|
|
153 | (1) |
|
Imaging of immunoglobulin G4-related orbital disease |
|
|
154 | (2) |
|
Histology of immunoglobulin G4-related orbital disease |
|
|
156 | (5) |
|
Treatment of immunoglobulin G4-related orbital disease |
|
|
161 | (1) |
|
|
|
162 | (3) |
|
|
|
162 | (3) |
|
|
|
|
|
|
|
|
|
|
|
|
165 | (1) |
|
|
|
166 | (1) |
|
|
|
166 | (1) |
|
Hypertrophic scars and keloids |
|
|
167 | (1) |
|
Patient considerations before scar modulation |
|
|
167 | (1) |
|
Timing of scar modulation |
|
|
168 | (1) |
|
Approaches to scar modulation |
|
|
169 | (1) |
|
|
|
169 | (1) |
|
|
|
169 | (1) |
|
Nonsurgical approaches to scar modulation |
|
|
169 | (7) |
|
|
|
169 | (3) |
|
|
|
172 | (1) |
|
|
|
173 | (1) |
|
|
|
174 | (2) |
|
Other agents and future therapies |
|
|
176 | (1) |
|
|
|
176 | (5) |
| Section VI Pediatric Opthalmology |
|
|
Amblyopia in the Twenty-First Century |
|
|
|
|
|
|
|
|
|
181 | (1) |
|
Significance/in-depth analysis |
|
|
182 | (5) |
|
|
|
182 | (1) |
|
|
|
182 | (1) |
|
|
|
183 | (4) |
|
Current relevance and future avenues to investigate |
|
|
187 | (3) |
|
|
|
187 | (1) |
|
|
|
188 | (1) |
|
|
|
189 | (1) |
|
Burden of amblyopia treatment |
|
|
190 | (1) |
|
|
|
190 | (3) |
|
Telemedicine in Retinopathy of Prematurity |
|
|
|
|
|
|
|
|
|
|
|
193 | (1) |
|
|
|
194 | (12) |
|
|
|
195 | (1) |
|
|
|
195 | (1) |
|
Data and image management |
|
|
196 | (1) |
|
The retinopathy of prematurity specialist |
|
|
196 | (1) |
|
|
|
197 | (3) |
|
|
|
200 | (1) |
|
|
|
200 | (1) |
|
|
|
201 | (5) |
|
Future research and trends |
|
|
206 | (1) |
|
New wide-field imaging cameras |
|
|
206 | (1) |
|
|
|
206 | (1) |
|
Software and autoanalysis |
|
|
206 | (1) |
|
Crowdsourcing in retinopathy of prematurity |
|
|
206 | (1) |
|
Government and financial support |
|
|
206 | (1) |
|
Changing paradigm in retinopathy of prematurity screening |
|
|
207 | (1) |
|
|
|
207 | (4) |
|
Congenital Cataract: Lessons Learned from Infant Aphakia Treatment Study |
|
|
|
|
|
|
|
211 | (1) |
|
Infant Aphakia Treatment Study: study design and clinical measures at enrollment |
|
|
212 | (1) |
|
Lessons learned from Infant Aphakia Treatment Study |
|
|
213 | (1) |
|
|
|
214 | (1) |
|
Intraocular lens power calculation and early refractive outcomes |
|
|
215 | (1) |
|
|
|
216 | (2) |
|
|
|
218 | (1) |
|
|
|
218 | (3) |
|
|
|
221 | (2) |
|
|
|
223 | (1) |
|
|
|
223 | (1) |
|
Nystagmus and fixation instabilities |
|
|
224 | (1) |
|
|
|
224 | (1) |
|
|
|
225 | (1) |
|
Total costs incurred by each treatment group |
|
|
225 | (1) |
|
|
|
226 | (5) |
| Section VII Neuro-opthalmology |
|
|
Objective Measures of Visual Function in Papilledema |
|
|
|
|
|
|
|
231 | (1) |
|
|
|
232 | (12) |
|
Basis of objective visual function measurements |
|
|
232 | (1) |
|
|
|
233 | (6) |
|
Full-field electroretinography and the photopic negative response |
|
|
239 | (4) |
|
Pattern electroretinography |
|
|
243 | (1) |
|
|
|
244 | (1) |
|
Current clinical relevance |
|
|
244 | (1) |
|
Future avenues for investigation |
|
|
244 | (1) |
|
|
|
245 | (4) |
|
New Advancements in Migraine Assessment and Treatment |
|
|
|
|
|
|
|
|
|
249 | (1) |
|
Classification of headache |
|
|
250 | (1) |
|
Classification of migraine |
|
|
250 | (4) |
|
|
|
251 | (1) |
|
|
|
252 | (1) |
|
Complications of migraine visual aura |
|
|
252 | (1) |
|
Migraine with aura: red flags |
|
|
253 | (1) |
|
Other migraine-related visual conditions |
|
|
253 | (1) |
|
|
|
254 | (1) |
|
|
|
255 | (2) |
|
|
|
255 | (1) |
|
|
|
256 | (1) |
|
Bio-behavioral strategies |
|
|
256 | (1) |
|
|
|
256 | (1) |
|
|
|
257 | (1) |
|
|
|
258 | (3) |
| Section VIII Opthalmic Pathology and Ocular Oncology |
|
|
Update on Tumor-Node-Metastasis Staging for Uveal Melanoma |
|
|
|
|
|
|
|
|
|
|
|
261 | (1) |
|
Prognostic indicators in uveal melanoma |
|
|
262 | (1) |
|
Classification of uveal melanoma |
|
|
263 | (1) |
|
Tumor-node-metastasis staging for uveal melanoma |
|
|
264 | (2) |
|
Updates to the 7th edition of tumor-node-metastasis staging for uveal melanoma |
|
|
266 | (1) |
|
|
|
266 | (1) |
|
|
|
267 | (1) |
|
|
|
267 | (1) |
|
Validation of tumor-node-metastasis staging for uveal melanoma |
|
|
267 | (2) |
|
|
|
268 | (1) |
|
Survival based on ciliary body involvement and extraocular extension |
|
|
268 | (1) |
|
Survival based on overall stage |
|
|
268 | (1) |
|
|
|
269 | (1) |
|
|
|
269 | (1) |
|
|
|
270 | (3) |
|
Intravitreal Chemotherapy for Retinoblastoma |
|
|
|
|
|
|
|
|
|
|
|
273 | (1) |
|
Indications and historical aspects |
|
|
274 | (1) |
|
|
|
275 | (1) |
|
|
|
275 | (1) |
|
|
|
276 | (1) |
|
|
|
276 | (1) |
|
Technique and safety considerations |
|
|
276 | (1) |
|
Efficacy of intravitreal chemotherapy |
|
|
277 | (3) |
|
Side effects of intravitreal chemotherapy |
|
|
280 | (1) |
|
|
|
280 | (1) |
|
Relevance to current treatment of retinoblastoma |
|
|
281 | (1) |
|
|
|
282 | (1) |
|
|
|
282 | (1) |
|
|
|
282 | (1) |
|
|
|
283 | (1) |
|
|
|
283 | (4) |
| Section IX Optometry |
|
|
The Amblyopia Treatment Studies: Implications for Clinical Practice |
|
|
|
|
|
|
|
|
|
287 | (2) |
|
Signs, symptoms, and quality-of-life concerns |
|
|
288 | (1) |
|
Historical perspective on amblyopia treatment |
|
|
288 | (1) |
|
Amblyopia Treatment Studies |
|
|
288 | (1) |
|
Results and clinical implications |
|
|
289 | (13) |
|
Prescribing guidelines for refractive error correction |
|
|
289 | (1) |
|
Optical treatment studies |
|
|
290 | (2) |
|
|
|
292 | (4) |
|
Treatment of older children with amblyopia |
|
|
296 | (2) |
|
|
|
298 | (2) |
|
|
|
300 | (1) |
|
|
|
300 | (1) |
|
|
|
301 | (1) |
|
|
|
302 | (5) |
|
|
|
303 | (4) |
|
Traumatic Brain Injury: Visual Consequences, Diagnosis, and Treatment |
|
|
|
|
|
|
|
|
|
|
|
|
|
307 | (6) |
|
Traumatic brain injury: the visual consequences, diagnosis, and treatment |
|
|
313 | (11) |
|
|
|
313 | (4) |
|
|
|
317 | (3) |
|
|
|
320 | (3) |
|
|
|
323 | (1) |
|
|
|
324 | (3) |
|
|
|
324 | (1) |
|
|
|
325 | (1) |
|
|
|
326 | (1) |
|
|
|
327 | (1) |
|
Future avenues to investigate |
|
|
327 | (1) |
|
Natural history of traumatic brain injury |
|
|
327 | (1) |
|
Quality-of-fife assessment questionnaire |
|
|
328 | (1) |
|
|
|
328 | (1) |
|
|
|
329 | (1) |
|
Further development of objective tests for detection of concussion/mild traumatic brain injury |
|
|
330 | (1) |
|
Objective visual biomarker(s) for concussion/mild traumatic brain injury |
|
|
330 | (1) |
|
|
|
330 | (1) |
|
|
|
330 | (6) |
|
Age-related Macular Degeneration Beyond the Age-related Eye Disease Study II |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
336 | (1) |
|
Supportive nutrients beyond Age-related Eye Disease Study I and II |
|
|
337 | (5) |
|
Glutathione master antioxidant and selenium status |
|
|
337 | (2) |
|
|
|
339 | (1) |
|
Tocotrienols and tocopherols |
|
|
340 | (1) |
|
|
|
340 | (1) |
|
Magnesium shortage with suboptimal magnesium2+/calcium2+ ratio affecting 50% of the United States population |
|
|
340 | (1) |
|
Maintenance of an antiinflammatory omega-6/omega-3 ratio and a high Holman Index with adequate docohexanoic acid intake |
|
|
341 | (1) |
|
Embracing high-dose zeaxanthin |
|
|
341 | (1) |
|
Embracing nitric oxide-promoting activities/nutrients for sustained choroidal vasodilation |
|
|
342 | (1) |
|
|
|
342 | (1) |
|
Minimizing environmental stress |
|
|
343 | (11) |
|
Chronic ascorbate depletion/dosing considerations |
|
|
343 | (1) |
|
Excess simple sugars against concurrent cellular ascorbate depletion (vitamin C deficiency) |
|
|
344 | (3) |
|
Folypharmacy and drug-induced nutrient and energy depletion |
|
|
347 | (1) |
|
Ubiquitous modern copper plumbing (United States) |
|
|
347 | (2) |
|
|
|
349 | (3) |
|
Iatrogenic calcification via overzealous calcium++ supplementation |
|
|
352 | (1) |
|
Maintaining a healthy gastrointestinal microbiome |
|
|
353 | (1) |
|
Genetics, zinc epigenetics, and hormetic adaptive response |
|
|
354 | (9) |
|
|
|
354 | (1) |
|
Epigenetics, the epigenome, and hormesis in postdarwinian biology |
|
|
355 | (2) |
|
General principles: actions of sirtuin 3 |
|
|
357 | (1) |
|
General principles: hormesis |
|
|
357 | (6) |
|
|
|
363 | (2) |
|
|
|
365 | (6) |
| Section X Glaucoma |
|
|
Recent Advances in the Pharmacotherapy for Glaucoma |
|
|
|
|
|
|
|
371 | (3) |
|
|
|
374 | (10) |
|
|
|
382 | (2) |
|
|
|
384 | (5) |
|
New Glaucoma Surgical Procedures |
|
|
|
|
|
|
|
|
|
|
|
389 | (1) |
|
|
|
390 | (16) |
|
|
|
390 | (11) |
|
|
|
401 | (1) |
|
|
|
402 | (4) |
|
|
|
406 | |
Lisainfo e-raamatute kohta